- Home
- RGF vs LGVN Comparison
RGF vs LGVN Comparison
Compare RGF & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGF
- LGVN
- Stock Information
- Founded
- RGF 2016
- LGVN 2014
- Country
- RGF United States
- LGVN United States
- Employees
- RGF N/A
- LGVN N/A
- Industry
- RGF Packaged Foods
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- RGF Consumer Staples
- LGVN Health Care
- Exchange
- RGF Nasdaq
- LGVN Nasdaq
- Market Cap
- RGF 8.3M
- LGVN 30.0M
- IPO Year
- RGF 2021
- LGVN 2021
- Fundamental
- Price
- RGF $0.36
- LGVN $2.05
- Analyst Decision
- RGF Hold
- LGVN Strong Buy
- Analyst Count
- RGF 1
- LGVN 2
- Target Price
- RGF $0.50
- LGVN $8.00
- AVG Volume (30 Days)
- RGF 1.2M
- LGVN 393.9K
- Earning Date
- RGF 11-08-2024
- LGVN 11-08-2024
- Dividend Yield
- RGF N/A
- LGVN N/A
- EPS Growth
- RGF N/A
- LGVN N/A
- EPS
- RGF N/A
- LGVN N/A
- Revenue
- RGF $156,379,000.00
- LGVN $1,229,000.00
- Revenue This Year
- RGF $23.67
- LGVN $161.78
- Revenue Next Year
- RGF N/A
- LGVN $8.62
- P/E Ratio
- RGF N/A
- LGVN N/A
- Revenue Growth
- RGF 18.88
- LGVN 39.34
- 52 Week Low
- RGF $0.21
- LGVN $0.77
- 52 Week High
- RGF $2.75
- LGVN $23.90
- Technical
- Relative Strength Index (RSI)
- RGF 45.74
- LGVN 52.20
- Support Level
- RGF $0.33
- LGVN $1.76
- Resistance Level
- RGF $0.40
- LGVN $2.26
- Average True Range (ATR)
- RGF 0.04
- LGVN 0.12
- MACD
- RGF 0.00
- LGVN 0.05
- Stochastic Oscillator
- RGF 56.82
- LGVN 58.00
About RGF The Real Good Food Company Inc.
The Real Good Food Company Inc is an high-growth, branded, health- and wellness-focused frozen food company. It develops, markets, and manufactures delicious and convenient comfort foods designed to be high in protein, low in sugar, and made from gluten- and grain-free ingredients that are intended to be sold in the health and wellness segment of the frozen food category. All of its revenue is derived from the United States.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.